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The immunosuppressive tumor microenvironment per-
turbs numerous immune regulatory networks and
usurps host antitumor immunity. We discovered that
tumor interferes with host hematopoietic Notch system
in lung cancer patients [1]. The resultant decrease in
immune Notch signaling could be a major causative link
in the inadequate induction of antitumor immunity.
Interestingly, administration of the novel Delta-like
ligand 1 (DLL1) multivalent cluster [1] and the FDA-
approved proteasome inhibitor drug bortezomib, which
also sensitizes tumors to death signals [2,3], restored the
tumor-induced decrease in immune Notch. Bortezomib
increased the expression of Notch target genes Hes1
and Hey1 in thymus, lymph node, and spleen of tumor-
bearing mice. Moreover, bortezomib administration
decreased the proportion of regulatory T cells and
enhanced antitumor T cell production of IFN-g. Results
indicate that bortezomib-induced activation of Notch
target genes Hes1 and Hey1 is through its inhibition of
NFB while its activation of Deltex1 is mediated via
PI3K. The potential of modulating antitumor Notch sig-
naling by the prototypic DLL1 cluster in combination
with bortezomib presents exciting opportunities to
uncover multi-pronged immune stimulatory regimens.
Therapeutic restoration of immune Notch signaling by
bortezomib could provide effective treatment and recur-
rence-free survival in cancer patients by breaking tumor
resistance, enhancing immune surveillance, and sustain-
ing robust anti-tumor immunity.
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